Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | The benefits of using patient reported outcomes in prostate cancer

Prantik Das • 8 Mar 2019
GU Cancers 2019
Genitourinary Cancer Prostate Cancer Pazopanib Sunitinib

Prantik Das, MBBS, MRCP, FRCR, of the Lincoln County Hospital, Lincoln, UK, discusses the results of using a patient reported outcomes tool to determine the effects of sunitinib and pazopanib on physical, social and emotional function. This interview was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Prantik Das

1:20
Unmet needs of immunotherapy for bladder cancer
Prantik Das • 18 Feb 2022
1:12
Unmet clinical needs in bladder cancer care in the UK
Prantik Das • 18 Feb 2022
2:12
Real-world study of atezolizumab vs. pembrolizumab for advanced/metastatic UC
Prantik Das • 18 Feb 2022
2:28
Hypofractionated radiotherapy for the management of prostate cancer
Prantik Das • 8 Mar 2019

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals